Cited by 860Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentBone health and treatments

The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Open access

Eisenberger, Mario A., Blumenstein, Brent A., Crawford, E. David, Miller, Gary, McLeod, David G., Loehrer, Patrick J., Wilding, George, Sears, Kathy, Culkin, Daniel J., Thompson, Ian M., Bueschen, Anton J., Lowe, Bruce A.·1998·New England Journal of Medicine

DOI 10.1056/nejm199810083391504

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Combined androgen blockade for the treatment of metastatic prostate cancer consists of an antiandrogen drug plus castration. In a previous trial, we found that adding the antiandrogen flutamide to leuprolide acetate (a synthetic gonadotropin-releasing hormone that results in medical ablation of testicular function) significantly improved survival as compared with that achieved with placebo plus leuprolide acetate. In the current trial, we compared flutamide plus bilateral orchiectomy with placebo plus orchiectomy. METHODS: We randomly assigned patients who had never received antiandrogen therapy and who had distant metastases from adenocarcinoma of the prostate to treatment with bilateral orchiectomy and either flutamide or placebo. Patients were stratified according to the extent of disease and according to performance status. RESULTS: Of the 1387 patients who were enrolled in the trial, 700 were randomly assigned to the flutamide group and 687 to the placebo group. Overall, the incidence of toxic effects was minimal; the only notable differences between the groups were the greater rates of diarrhea and anemia with flutamide. There was no significant difference between the two groups in overall survival (P=0.14). The estimated risk of death (hazard ratio) for flutamide as compared with placebo was 0.91 (90 percent confidence interval, 0.81 to 1.01). Flutamide was not associated with enhanced benefit in patients with minimal disease. CONCLUSIONS: The addition of flutamide to bilateral orchiectomy does not result in a clinically meaningful improvement in survival among patients with metastatic prostate cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199810083391504

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate
Huggins, C., & Hodges, C. V. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,856
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Cancer statistics, 1997
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,000
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Self-citation
Leuprolide versus Diethylstilbestrol for Metastatic Prostate Cancer
The Leuprolide Study Group (1984) · New England Journal of Medicine · doi:10.1056/nejm198411153112004 · Cited by 622
The veterans administration cooperative urological research group's studies of cancer of the prostate
Byar, D. P. (1973) · Cancer · doi:10.1002/1097-0142(197311)32:5 · Cited by 595
Designs for group sequential tests
Fleming, T. R., Harrington, D. P., & O’Brien, P. C. (1984) · Controlled Clinical Trials · doi:10.1016/s0197-2456(84)80014-8 · Cited by 354
Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients
Prostate Cancer Trialists' Collaborative Group (1995) · The Lancet · doi:10.1016/s0140-6736(95)92163-x · Cited by 320
Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation
Rubinstein, L., Gail, M. H., & Santner, T. J. (1981) · Journal of Chronic Diseases · doi:10.1016/0021-9681(81)90007-2 · Cited by 270

Show all 25 references

Research works printed but not linked: 3

Huggins C, 1941, Cancer Res, 1, 293
10.1002/1097-0142(19931215)72:12+<3834::AID-CNCR2820721714>3.0.CO;2-Z · DOI
Eisenberger MA, 1994, Semin Oncol, 21, 613

Sorted by citations

Items 501–600 of 860

Prostate radiotherapy in newly diagnosed metastatic prostate cancer
Ali, A., Parker, C. C., & Clarke, N. W. (2019) · Current Opinion in Urology · doi:10.1097/mou.0000000000000675 · Cited by 10
The role of SPDEF in cancer: promoter or suppressor
Bao, K.-C., & Wang, F. (2022) · Neoplasma · doi:10.4149/neo_2022_220529n571 · Cited by 10
Statistical Significance in Biology: Neither Necessary Nor Sufficient for Hypothesis Acceptance
Shrader‐Frechette, K. (2008) · Biological Theory · doi:10.1162/biot.2008.3.1.12 · Cited by 10
Docetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer : Comparative Analysis between 1st-line and 2nd-line Docetaxel
Joung, J. Y., Jeong, I. G., Han, K. S., Kim, T. S., Yang, S. O., Seo, H. K., Chung, J., Cho, K. S., & Lee, K. H. (2008) · Yonsei Medical Journal · doi:10.3349/ymj.2008.49.5.775 · Cited by 10
Radiotherapy Combined With Androgen Deprivation for Bone Oligometastases After Primary Curative Radiotherapy for Prostate Cancer
Wu, J., Lin, L., He, J., Liang, H., & Li, J. (2016) · Medicine · doi:10.1097/md.0000000000002789 · Cited by 10
Review: TRP family proteins in the lower urinary tract: translating basic science into new clinical prospective
Lazzeri, M., Costantini, E., & Porena, M. (2009) · Therapeutic Advances in Urology · doi:10.1177/1756287209103922 · Cited by 10
Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?
Canby‐Hagino, E., Swanson, G. P., Crawford, E. D., Basler, J. W., Hernández, J., & Thompson, I. M. (2005) · Current Urology Reports · doi:10.1007/s11934-005-0006-5 · Cited by 10
Self-citation
Controversies of Androgen Ablation Therapy for Metastatic Prostate Cancer
Wilson, S., & C., E. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206776056056 · Cited by 10
The changing face of hormonal therapy for prostate cancer
Šeruga, B., & Tannock, I. F. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn477 · Cited by 10
Drug development for noncastrate prostate cancer in a changed therapeutic landscape
Teo, M. Y., O’Shaughnessy, M. J., McBride, S. M., Vargas, H. A., & Scher, H. I. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.160 · Cited by 10
Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro‐Oncology
Poon, D. M. C., Chan, C.-K., Chan, T., Cheung, F., Kwong, P. W., Lee, E. K., Leung, A. K., Leung, S. Y., Ma, W., So, H., et al. (2017) · British Journal of Urology · doi:10.1111/bju.14091 · Cited by 10
Combination hormonal therapy: a reassessment within advanced prostate cancer
Moul, J. W., & Chodak, G. W. (2004) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500741 · Cited by 10
Paradigms in androgen/castrate resistant states of prostate cancer in a biomarker era
Bianco, F. J. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.11.002 · Cited by 10
Evolution of therapeutic approaches with luteinizing hormone–releasing hormone agonists in 2003
Moul, J. W., & Fowler, J. E. (2003) · Urology · doi:10.1016/j.urology.2003.10.014 · Cited by 10
The management of prostate cancer in patients with a rising prostate‐specific antigen level
Fichtner, J. (2000) · British Journal of Urology · doi:10.1046/j.1464-410x.2000.00703-4.x · Cited by 10
Apoptotic pathways in prostate cancer
Denmeade, S. R., TOMBAL, B. F., & Isaacs, J. T. (2001) · Advances in cell aging and gerontology · doi:10.1016/s1566-3124(01)06002-3 · Cited by 10
Clinical Strategies in the Management of Biochemical Recurrence After Radical Prostatectomy
Zimmerman, R. A., & Culkin, D. J. (2003) · Clinical Prostate Cancer · doi:10.3816/cgc.2003.n.024 · Cited by 10
Self-citation
Hormone naïve prostate cancer: predicting and maximizing response intervals
Moul, J. W. (2015) · Asian Journal of Andrology · doi:10.4103/1008-682x.152821 · Cited by 9
Treatment of Castration-Resistant Prostate Cancer
Antonarakis, E. S., Carducci, M. A., & Eisenberger, M. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00110-9 · Cited by 9
Self-citation
Combined Ligand/Structure-Based Virtual Screening and Molecular Dynamics Simulations of Steroidal Androgen Receptor Antagonists
Wang, Y., Han, R., Zhang, H., Liu, H., Li, J., Liu, H., & Gramatica, P. (2017) · BioMed Research International · doi:10.1155/2017/3572394 · Cited by 9
A critical review of maximal androgen blockade for advanced prostate cancer.
Chodak, G. W. (2004) · Europe PMC (PubMed Central) · Cited by 9
Phase II Trial of Estramustine and Etoposide in Androgen-Sensitive Metastatic Prostate Carcinoma
Vaishampayan, U. N., Fontana, J. A., Du, W., & Hussain, M. (2004) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000135922.12198.e4 · Cited by 9
Chemoprevention of Prostate Cancer
Brand, T. C., Canby‐Hagino, E., Kumar, A., Ghosh, R., Leach, R. J., & Thompson, I. M. (2006) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2006.03.012 · Cited by 9
Self-citation
What does prostate-specific antigen recurrence mean?
Pound, C. R., & Partin, A. W. (2000) · Current Urology Reports · doi:10.1007/s11934-000-0032-2 · Cited by 9
Prostate Cancer Prevention: What Do We Know Now, and When Will We Know More?
Thompson, I. M., Basler, J. W., Hensley, D., von Merveldt, D., Jenkins, C. A., Higgins, B., Leach, R. J., Troyer, D. A., & Pollock, B. H. (2003) · Clinical Prostate Cancer · doi:10.3816/cgc.2003.n.002 · Cited by 9
Self-citation
Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer
Hellerstedt, B. A. (2003) · Urology · doi:10.1016/j.urology.2003.09.002 · Cited by 9
Revolutions in the Management of Hormone-Refractory Prostate Cancer
Abrahamsson, P. (2003) · European Urology Supplements · doi:10.1016/s1569-9056(02)00201-4 · Cited by 9
To eat or not to eat: a critical review on the role of autophagy in prostate carcinogenesis and prostate cancer therapeutics
Kurganovs, N. J., & Engedal, N. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1419806 · Cited by 10
A new flavonoid derivative exerts antitumor effects against androgen‐sensitive to cabazitaxel‐resistant prostate cancer cells
Naito, R., Kano, H., Shimada, T., Makino, T., Kadomoto, S., Iwamoto, H., Yaegashi, H., Izumi, K., Kadono, Y., Nakata, H., et al. (2021) · The Prostate · doi:10.1002/pros.24106 · Cited by 8
A review of clinical evidence to assess differences in efficacy and safety of luteinizing hormone–releasing hormone (LHRH) agonist (goserelin) and LHRH antagonist (degarelix)
Bahl, A., Rajappa, S. J., Rawal, S. K., Bakshi, G., Murthy, V., & Patil, K. (2022) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_1415_20 · Cited by 8
The role of chemotherapy in metastatic prostate cancer
Riaz, I. B., & Sweeney, C. J. (2022) · Current Opinion in Urology · doi:10.1097/mou.0000000000000985 · Cited by 10
Oral chemotherapeutic agents in metastatic hormone-sensitive prostate cancer: A network meta-analysis of randomized controlled trials
Lee, Y. S., Kim, S. H., Tae, J. H., Chang, I. H., Kim, T., Myung, S. C., Kim, M.-S., Nguyen, T. T., Choi, J., Kim, J. H., et al. (2023) · Prostate International · doi:10.1016/j.prnil.2023.06.003 · Cited by 8
Recent advances in chemotherapy for advanced prostate cancer
Olson, K. B., & Pienta, K. J. (2000) · Current Urology Reports · doi:10.1007/s11934-000-0035-z · Cited by 8
Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
Lü, Q., Williams, A. K., Chalasani, V., Martínez, C. H., & Chin, J. L. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.538677 · Cited by 8
Cancer therapeutics-related cardiac dysfunction in a patient treated with abiraterone for castration-resistant prostate cancer
Tsugu, T., Nagatomo, Y., Nakajima, Y., Kageyama, T., Akise, Y., Endo, J., Itabashi, Y., Murata, M., & Mitamura, H. (2018) · Journal of Medical Ultrasonics · doi:10.1007/s10396-018-0897-7 · Cited by 8
Androgen deprivation and other treatments for advanced prostate cancer.
Brawer, M. K., Crawford, E. D., Labrie, F., Mendoza-Valdés, A., Miller, P. D., & Petrylak, D. P. (2001) · Europe PMC (PubMed Central) · Cited by 8
Self-citation
Prostate‐specific antigen half‐life and pretreatment prostate‐specific antigen: Crucial predictors for prostate‐specific antigen trend in delayed‐combined androgen blockade therapy
Soga, N., Onishi, T., Arima, K., & Sugimura, Y. (2007) · International Journal of Urology · doi:10.1111/j.1442-2042.2007.01671.x · Cited by 8
Prognostic Factor Analysis in Patients with Advanced Prostate Cancer Treated by Castration Plus Anandron or Placebo: A Final Update
de Reijke, T. M., & Derobert, E. (2002) · European Urology · doi:10.1016/s0302-2838(02)00272-5 · Cited by 8
Behavioral Science Research in the Cooperative Group Setting: the Southwest Oncology Group Experience
Gotay, C. C. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.17.1381 · Cited by 8
Beyond the Androgen Receptor: Targeting Actionable Drivers of Prostate Cancer
Nelson, P. S. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00064 · Cited by 8
Population pharmacokinetic–pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelin
Snelder, N., Drenth, H., Bergmann, K. R., Wood, N., Hibberd, M., & Scott, G. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13891 · Cited by 7
Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review
Meagher, M. F., Salmasi, A., & Stewart, T. F. (2023) · Research and Reports in Urology · doi:10.2147/rru.s398129 · Cited by 7
Efficacy of Bicalutamide 150-mg Monotherapy Compared With Combined Androgen Blockade in Patients With Locally Advanced Prostate Cancer
Kang, Y., Kim, K. H., & Lee, K. S. (2014) · Korean journal of urology · doi:10.4111/kju.2014.55.5.315 · Cited by 7
Actions of Estrogenic Endocrine Disrupting Chemicals on Human Prostate Stem/Progenitor Cells and Prostate Carcinogenesis
Hu, D.-P., Hu, W., Xie, L., Li, Y., Birch, L. A., & Prins, G. S. (2016) · The Open Biotechnology Journal · doi:10.2174/1874070701610010076 · Cited by 7
Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer
Kohli, M., & Shenoy, N. K. (2016) · Indian Journal of Urology · doi:10.4103/0970-1591.191234 · Cited by 7
Effect of adjuvant hormone therapy in patients with prostate cancer
Liu, F., Sun, D., Zhou, X., Ding, Y., Ma, Y., Hou, Y., Kong, X., & Wang, Z. (2018) · Medicine · doi:10.1097/md.0000000000013145 · Cited by 7
A multicenter observational study of the real‐world use of docetaxel for metastatic castration‐resistant prostate cancer in China
He, D., Sun, Z., Guo, J., Zhang, Z., Shan, Y., Ma, L., Li, H., Jin, J., Huang, Y., Xiao, J., et al. (2019) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13142 · Cited by 7
Analysis of urological procedures in men who died from prostate cancer using a population‐based approach
Babaian, K. N., Truong, M., Cetnar, J. P., Cross, D. S., Shi, F., Ritter, M. A., & Jarrard, D. F. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11517.x · Cited by 7
Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment
Nakai, Y., Nishimura, K., Nakayama, M., Uemura, M., Takayama, H., Nonomura, N., & Tsujimura, A. (2013) · International Journal of Clinical Oncology · doi:10.1007/s10147-013-0536-7 · Cited by 7
Management of Hormone-Sensitive Metastatic Prostate Cancer
Agarwal, N., & Hussain, M. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.08.007 · Cited by 7
Pharmacotherapy for prostate cancer, with emphasis on hormonal treatments
Barmoshe, S., & Zlotta, A. R. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.13.1685 · Cited by 7
Combined modality treatment for prostate cancer: role of chemotherapy
Sandler, H. M. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00274-4 · Cited by 7
Androgen Receptor-dependent Expression of Low-density Lipoprotein Receptor-related Protein 6 is Necessary for Prostate Cancer Cell Proliferation
Park, E., Kim, E. K., Kim, M. K., Ha, J. M., Kim, Y. W., Jin, S. Y., Shin, H. K., Ha, H. K., Lee, J. Z., & Bae, S. S. (2015) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2015.19.3.235 · Cited by 7
Impact of High-Volume Disease in Asian Population with Newly Diagnosed Metastatic Prostate Cancer
Cheng, Y.-T., Hong, J., Lu, Y.-C., Pu, Y., Huang, C., Huang, K., Liu, S., & Chen, C. (2018) · Urological Science · doi:10.4103/uros.uros_11_18 · Cited by 7
A novel GPCR target in correlation with androgen deprivation therapy for prostate cancer drug discovery
Tian, J., Chi, C., Bian, G., Guo, F., Wang, X., & Yu, B. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13499 · Cited by 7
Prognostic impact of bone metastatic volume beyond vertebrae and pelvis in patients with metastatic hormone-sensitive prostate cancer
Suzuki, K., Okamura, Y., Hara, T., Terakawa, T., Furukawa, J., Harada, K., Hinata, N., & Fujisawa, M. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01931-x · Cited by 7
Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective.
Taplin, M. (2003) · Europe PMC (PubMed Central) · Cited by 7
Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer
Zeliadt, S. B., & Penson, D. F. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725040-00004 · Cited by 7
Discovery and structure–activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists
Tachibana, K., Imaoka, I., Yoshino, H., Kato, N., Nakamura, M., Ohta, M., Kawata, H., Taniguchi, K., Ishikura, N., Nagamuta, M., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.07.090 · Cited by 7
New opportunities in the management of prostate cancer–related bone complications
Smith, M. R., Brown, G. A., & Fred Saad, C. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.08.004 · Cited by 7
Inosine Monophosphate Dehydrogenase 2 as a marker of aggressive and advanced prostate cancer
Wieczorek, P., Bałut-Wieczorek, M., Jasiński, M., Szabłoński, W., & Antczak, A. (2018) · Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication · doi:10.5173/ceju.2018.1696 · Cited by 7
The management of prostate cancer in patients with a rising prostate‐specific antigen level
Fichtner, J. (2000) · British Journal of Urology · doi:10.1046/j.1464-410x.2000.00701.x · Cited by 7
Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer
Hoffmann, J., & Sommer, A. (2006) · Topics in medicinal chemistry · doi:10.1007/7355_2006_002 · Cited by 7
Is flutamide effective in patients with bilateral orchiectomy?
Rothman, K. J., Johnson, E. S., & Sugano, D. S. (1999) · The Lancet · doi:10.1016/s0140-6736(05)74403-2 · Cited by 7
Quality of life studies and genito-urinary tumors
Bertetto, O., Sergio Bracarda, A., Tamburini, M., & Cortesi, E. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_3.s43 · Cited by 7
New drugs for prostate cancer
Alifrangis, C., Brown, C. O., Tuthill, M. H., & Waxman, J. (2011) · British Journal of Urology · doi:10.1111/j.1464-410x.2011.10570.x · Cited by 6
Systemic Therapy for the Treatment of Hormone-Sensitive Metastatic Prostate Cancer: from Intermittent Androgen Deprivation Therapy to Chemotherapy
Liaw, B. C.-H., Shevach, J. W., & Oh, W. K. (2015) · Current Urology Reports · doi:10.1007/s11934-015-0486-x · Cited by 6
5α-Reductase Inhibition Coupled with Short Off Cycles Increases Survival in the LNCaP Xenograft Prostate Tumor Model on Intermittent Androgen Deprivation Therapy
Pascal, L. E., Masoodi, K. Z., O’Malley, K. J., Shevrin, D. H., Gingrich, J. R., Parikh, R. A., & Wang, Z. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.10.101 · Cited by 6
The Timing and Extent of Androgen Deprivation Therapy for Prostate Cancer: Weighing the Clinical Evidence
Ginzburg, S., & Albertsen, P. C. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.05.005 · Cited by 6
Evolving Use of Androgen Deprivation Therapy in Prostate Cancer Management
Mohler, J. L. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0186 · Cited by 6
Osteoblasts Generate Testosterone From DHEA and Activate Androgen Signaling in Prostate Cancer Cells
Moon, H. H., Clines, K. L., O’Day, P., Al-Barghouthi, B. M., Farber, E., Farber, C. R., Auchus, R. J., & Clines, G. A. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4313 · Cited by 8
A systematic review evaluating the effectiveness of exercise training on physical condition in prostate cancer patients undergoing androgen deprivation therapy
Yuan, F., Wang, Y., Xiao, X., Zhang, X., Jing, M., Kamecki, H., Tan, Y. G., Barreras, S. G., Aragon‐Ching, J. B., Ma, Z., et al. (2023) · Translational Andrology and Urology · doi:10.21037/tau-23-272 · Cited by 7
Dynamic prediction of metastases after radical prostatectomy for prostate cancer
Inman, B. A., Frank, I., Boorjian, S. A., Akornor, J. W., Karnes, R. J., Leibovich, B. C., Blute, M. L., & Bergstralh, E. J. (2011) · British Journal of Urology · doi:10.1111/j.1464-410x.2011.10208.x · Cited by 6
Therapeutic options and multifaceted treatment paradigms in metastatic castrate-resistant prostate cancer
Vaishampayan, U. N. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000066 · Cited by 6
Novel hormonal approaches in prostate cancer
Friedlander, T. W., & Ryan, C. J. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0032-4 · Cited by 6
Biochemical recurrence of prostate cancer
Moul, J. W. (2003) · Current Problems in Cancer · doi:10.1016/s0147-0272(03)00032-1 · Cited by 6
Review: Risk stratification in the hormonal treatment of patients with prostate cancer
Uhlman, M. A., Moul, J. W., Tang, P., Stackhouse, D. A., & Sun, L. L. (2009) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009340164 · Cited by 6
Cancer de la prostate et hormonothérapie : indications thérapeutiques de première ligne
BOCCON-GIBOD, L., Richaud, P. M., Coloby, P. J., Coulange, C., Culine, S., Davin, J., Soulie, M., & Zerbib, M. (2009) · The French Journal of Urology · doi:10.1016/j.purol.2009.11.001 · Cited by 6
Hormonal therapy options for prostate‐specific antigen‐only recurrence of prostate cancer after previous local therapy
Moul, J. W., & Zlotta, A. R. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05284.x · Cited by 6
A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score
Yamaguchi, Y., Hayashi, Y., Ishizuya, Y., Takeda, K., Nakai, Y., Arai, Y., Nakayama, M., Kakimoto, K., & Nishimura, K. (2014) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyu186 · Cited by 6
The evolving role of systemic therapy in high risk prostate cancer: strategies for cure in the 21st century
Vaishampayan, U. N., & Hussain, M. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00187-1 · Cited by 6
RETRACTED: Horizon scanning for novel therapeutics for the treatment of prostate cancer
Bianchini, D., Zivi, A., Sandhu, S. K., & Bono, J. S. D. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.514261 · Cited by 6
Retracted
Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer
Roth, A. R., Harmon, S. A., Perk, T., Eickhoff, J. C., Choyke, P. L., Kurdziel, K., Dahut, W. L., Apolo, A. B., Morris, M. J., Perlman, S. B., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.05.013 · Cited by 6
Association Between CYP17A1, CYB5A Polymorphisms and Efficacy of Abiraterone Acetate/Prednisone Treatment in Castration-Resistant Prostate Cancer Patients
Wu, X., Xu, Q., Chen, P.-Z., Yu, C., Ye, L., & Li, T. (2020) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s245086 · Cited by 7
Prostate Cancer
Nelson, W. G., Antonarakis, E. S., Carter, H. B., Marzo, A. M. D., & DeWeese, T. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00081-5 · Cited by 6
Chemotherapy in the Treatment of Prostate Cancer — The Past, the Present, and the Future
Sundararajan, S., & Vogelzang, N. J. (2014) · American Journal of Hematology / Oncology® · Cited by 6
Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy
Govindarajan, R., Khan, M. A., Gujja, S., & Holt, A. (2014) · Cancer Management and Research · doi:10.2147/cmar.s74116 · Cited by 6
Hormone Therapy in Advanced Prostate Cancer
Forster, T. H., Stoffel, F., & Gasser, T. C. (2002) · KARGER eBooks · doi:10.1159/000061329 · Cited by 6
Survival of Patients Who Had Salvage Castration After Failure on Bicalutamide Monotherapy for Stage (D2) Prostate Cancer
Kasimis, B. S., Wilding, G., Kreis, W., Feuerman, M., Chang, V. T.-S., Hwang, S. S., Steafather, H., COGSWELL, J., Rae, C., & Blumenfrucht, M. J. (2000) · Cancer Investigation · doi:10.3109/07357900009032826 · Cited by 6
Self-citation
Prostate Cancer Metastatic to the Pancreas
Wang, W., Stroehlein, J. R., Landon, G., & Ross, W. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.1427 · Cited by 6
The use of placebo in a trial of rectal artesunate as initial treatment for severe malaria patients en route to referral clinics: ethical issues
Kitua, A. Y., Folb, P. I., Warsame, M., Binka, F. N., Faiz, A., Ribeiro, I., Peto, T. J., Gyapong, J. O., Yunus, E. B., Rahman, R., et al. (2010) · Journal of Medical Ethics · doi:10.1136/jme.2009.030874 · Cited by 6
A Prospective Randomized Multicenter Study of Chlormadinone Acetate versus Flutamide in Total Androgen Blockade for Prostate Cancer
Ozono, S. (2000) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyd106 · Cited by 6
PET/CT imaging and the oligometastatic prostate cancer patient: an opportunity for a curative approach with high-dose radiotherapy?
Miralbell, R., & Buchegger, F. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2793-8 · Cited by 6
Hormonal Implications in the Development and Treatment of Prostate Cancer
Ip, C. C. K., & Hall, S. J. (2007) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.03.009 · Cited by 6
An update on prostate cancer research
Small, E. J., & Reese, D. (2000) · Current Opinion in Oncology · doi:10.1097/00001622-200005000-00014 · Cited by 6
Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancer
Ersoy-Fazlioglu, B., Lingadahalli, S., Altıntaş, U. B., Cingöz, A., Tekoglu, E., Yu, I. P. L., Dikbas, U. M., Missaghimamaghani, O., Yavuz, K., Adomat, H. H., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2500327122 · Cited by 8
Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives
Turco, F., Buttigliero, C., Delcuratolo, M. D., Gillessen, S., Vogl, U. M., Zilli, T., Fossati, N., Andrea Gallina, A., Farinea, G., Stefano, R. F. D., et al. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102138 · Cited by 5
The Expression Signature of Androgen Receptor Splice Variants and Their Distinctive Transcriptional Activities in Castration-Resistant Prostate Cancer
Plymate, S. R., & Luo, J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6182-1_13 · Cited by 5
Development and validation of a novel risk model in newly diagnosed de novo bone metastatic prostate cancer (M1b): a retrospective study
Zhang, Y., Wang, J., Ding, L., Zheng, Y., Wu, C., Wang, K., Xia, W., & Ge, P. (2023) · PeerJ · doi:10.7717/peerj.14615 · Cited by 5
Is Docetaxel Chemotherapy a New Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer?
Liaw, B. C.-H., & Oh, W. K. (2015) · American Journal of Hematology / Oncology® · Cited by 5

Authors: Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., Bueschen, A. J., & Lowe, B. A.
Affiliations: Johns Hopkins Hospital (US)
SWOG Cancer Research Network (US)
University of Colorado Denver (US)
Walter Reed National Military Medical Center (US)
University of Wisconsin–Madison (US)
University of Oklahoma Health Sciences Center (US)
University of Alabama at Birmingham (US)
Oregon Health & Science University (US)
ORCID: Eisenberger, Mario A.
Blumenstein, Brent A.
Crawford, E. David
McLeod, David G.
Loehrer, Patrick J.
Wilding, George
Culkin, Daniel J.
Thompson, Ian M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1998-10-08
Volume: 339
Issue: 15
Pages: 1036-1042
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199810083391504
OpenAlex: W2003985632
Cited by: 859
References: 25
Citations by year: 2026: 2 · 2025: 5 · 2024: 8 · 2023: 12 · 2022: 20 · 2021: 15 · 2020: 21 · 2019: 26 · 2018: 25 · 2017: 23 · 2016: 34 · 2015: 52 · 2014: 49 · 2013: 51 · 2012: 37
FWCI: 37.16
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (2u10ca038926-25)
National Cancer Institute (CA-32102, CA 42777, U10CA032102, U10CA042777, CA 38926)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords: metastatic prostate cancer, bilateral orchiectomy, flutamide, combined androgen blockade, leuprolide, antiandrogen therapy, overall survival, adverse effects, anemia, diarrhea
MeSH terms: Adenocarcinoma, Adult, Aged, Aged, 80 and over, Androgen Antagonists, Bone Neoplasms, Combined Modality Therapy, Double-Blind Method, Flutamide, Humans, Male, Middle Aged, Orchiectomy, Prostatic Neoplasms, Soft Tissue Neoplasms, Survival Analysis, Prostate-Specific Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks